دورية أكاديمية
أعرض في EDS

Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.

التفاصيل البيبلوغرافية
العنوان: Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.
المؤلفون: Arita Y; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. yukiarita1113@gmail.com., Woo S; Department of Radiology, NYU Langone Health, New York, USA., Kwee TC; Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands., Shigeta K; Department of Urology, Keio University School of Medicine, Tokyo, Japan., Ueda R; Office of Radiation Technology, Keio University Hospital, Tokyo, Japan., Nalavenkata S; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA., Edo H; Department of Radiology, National Defense Medical Collage, Saitama, Japan., Miyai K; Department of Pathology and Laboratory Medicine, National Defense Medical College, Saitama, Japan., Das J; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA., Andrieu PIC; Department of Radiology, Mayo Clinic, Rochester, USA., Vargas HA; Department of Radiology, NYU Langone Health, New York, USA.
المصدر: Abdominal radiology (New York) [Abdom Radiol (NY)] 2024 Aug; Vol. 49 (8), pp. 2797-2811. Date of Electronic Publication: 2024 Jun 07.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101674571 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2366-0058 (Electronic) NLM ISO Abbreviation: Abdom Radiol (NY) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Springer, [2016]-
مواضيع طبية MeSH: Urinary Bladder Neoplasms*/diagnostic imaging , Urinary Bladder Neoplasms*/pathology , Multiparametric Magnetic Resonance Imaging*/methods , Carcinoma, Transitional Cell*/diagnostic imaging , Carcinoma, Transitional Cell*/pathology, Humans ; Contrast Media ; Neoplasm Invasiveness ; Diagnosis, Differential ; Urinary Bladder/diagnostic imaging ; Urinary Bladder/pathology
مستخلص: Bladder cancer (BC), predominantly comprising urothelial carcinomas (UCs), ranks as the tenth most common cancer worldwide. UCs with variant histology (variant UC), including squamous differentiation, glandular differentiation, plasmacytoid variant, micropapillary variant, sarcomatoid variant, and nested variant, accounting for 5-10% of cases, exhibit more aggressive and advanced tumor characteristics compared to pure UC. The Vesical Imaging-Reporting and Data System (VI-RADS), established in 2018, provides guidelines for the preoperative evaluation of muscle-invasive bladder cancer (MIBC) using multiparametric magnetic resonance imaging (mpMRI). This technique integrates T2-weighted imaging (T2WI), dynamic contrast-enhanced (DCE)-MRI, and diffusion-weighted imaging (DWI) to distinguish MIBC from non-muscle-invasive bladder cancer (NMIBC). VI-RADS has demonstrated high diagnostic performance in differentiating these two categories for pure UC. However, its accuracy in detecting muscle invasion in variant UCs is currently under investigation. These variant UCs are associated with a higher likelihood of disease recurrence and require precise preoperative assessment and immediate surgical intervention. This review highlights the potential value of mpMRI for different variant UCs and explores the clinical implications and prospects of VI-RADS in managing these patients, emphasizing the need for careful interpretation of mpMRI examinations including DCE-MRI, particularly given the heterogeneity and aggressive nature of variant UCs. Additionally, the review addresses the fundamental MRI reading procedures, discusses potential causes of diagnostic errors, and considers future directions in the use of artificial intelligence and radiomics to further optimize the bladder MRI protocol.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Choy B, Tretiakova M, Zynger DL (2024) What’s new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis. J Pathol Transl Med 58:45–8. (PMID: 3814590410.4132/jptm.2023.12.11)
Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, et al (2013) A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 63:321–32. (PMID: 2308899610.1016/j.eururo.2012.10.008)
Wang G, McKenney JK (2019) Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med 143:571–7. (PMID: 3004412410.5858/arpa.2017-0539-RA)
Black PC, Brown GA, Dinney CP (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27:3–7. (PMID: 1836710710.1016/j.urolonc.2007.07.010)
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, et al (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol 85:17–31. (PMID: 3785845310.1016/j.eururo.2023.08.016)
Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, et al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74:294–306. (PMID: 29755006669049210.1016/j.eururo.2018.04.029)
Panebianco V, Briganti A, Boellaard TN, Catto J, Comperat E, Efstathiou J, et al (2023) Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System. Nat Rev Urol. https:// https://doi.org/10.1038/s41585-023-00830-2 . (PMID: 10.1038/s41585-023-00830-238036666)
Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al (2020) Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 3:306–15. (PMID: 32199915729394010.1016/j.euo.2020.02.007)
Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D’Andrea D, Messina E, et al (2022) The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol 40:1617–28. (PMID: 35294583923700310.1007/s00345-022-03969-6)
Arita Y, Shigeta K, Akita H, Suzuki T, Kufukihara R, Kwee TC, et al (2021) Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol 31:875–83. (PMID: 3282941810.1007/s00330-020-07153-5)
Wang H, Luo C, Zhang F, Guan J, Li S, Yao H, et al (2019) Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology 291:668–74. (PMID: 3101281410.1148/radiol.2019182506)
Jazayeri SB, Dehghanbanadaki H, Hosseini M, Taghipour P, Alam MU, Balaji KC, et al (2022) Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis. Urol Oncol 40:45–55. (PMID: 3489599610.1016/j.urolonc.2021.11.008)
Arita Y, Yoshida S, Shigeta K, Kwee TC, Edo H, Okawara N, Hashimoto M, Ishii R, Ueda R, Mikami S, Fujiwara M, Waseda Y, Kikuchi E, Fujii Y, Jinzaki M (2023) Diagnostic value of the vesical imaging-reporting and data system in bladder urothelial carcinoma with variant histology. Eur Urol Oncol 6(1):99–102. (PMID: 3593326610.1016/j.euo.2022.07.006)
Arita Y, Kwee TC, Woo S, Shigeta K, Ishii R, Okawara N, et al (2023) Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System. Eur Urol Focus. https://doi.org/10.1016/j.euf.2023.08.004 . (PMID: 10.1016/j.euf.2023.08.00437633790)
Jafari NV, Rohn JL (2022) The urothelium: a multi-faceted barrier against a harsh environment. Mucosal Immunol 15:1127–42. (PMID: 36180582970525910.1038/s41385-022-00565-0)
Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, et al (2014) Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol 16:469–78. (PMID: 24747439419694610.1038/ncb2956)
Andersson KE, McCloskey KD (2014) Lamina propria: the functional center of the bladder? Neurourol Urodyn 33:9–16. (PMID: 2384701510.1002/nau.22465)
Narumi Y, Kadota T, Inoue E, Kuriyama K, Horinouchi T, Kasai K, et al (1993) Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology 187:151–5. (PMID: 845140310.1148/radiology.187.1.8451403)
Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R (2007) The value of hyoscine butylbromide in pelvic MRI. Clin Radiol 62:1087–93. (PMID: 1792086810.1016/j.crad.2007.05.007)
Caglic I, Panebianco V, Vargas HA, Bura V, Woo S, Pecoraro M, et al (2020) MRI of Bladder Cancer: Local and Nodal Staging. J Magn Reson Imaging 52:649–67. (PMID: 3211250510.1002/jmri.27090)
Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone MD, et al (2017) An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 27:3759–66. (PMID: 2818105410.1007/s00330-017-4758-3)
Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T, et al (2009) Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology. 251:112-21. (PMID: 1933284910.1148/radiol.2511080873)
Wang F, Jin D, Hua XL, Zhao ZZ, Wu LM, Chen WB, et al (2018) Investigation of diffusion kurtosis imaging for discriminating tumors from inflammatory lesions after treatment for bladder cancer. J Magn Reson Imaging 48:259–65. (PMID: 2923202110.1002/jmri.25924)
van der Pol CB, Chung A, Lim C, Gandhi N, Tu W, McInnes MDF, et al (2018) Update on multiparametric MRI of urinary bladder cancer. J Magn Reson Imaging 48:882–96. (PMID: 3022180110.1002/jmri.26294)
Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J (2000) A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int 85:32–6. (PMID: 1061994110.1046/j.1464-410x.2000.00358.x)
Hoegger MJ, Strnad BS, Ballard DH, Siegel CL, Shetty AS, Weimholt RC, et al (2023) Urinary Bladder Masses, Rare Subtypes, and Masslike Lesions: Radiologic-Pathologic Correlation. Radiographics 43:e220034. (PMID: 3649021010.1148/rg.220034)
Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH (2018) Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 211:W226–w41. (PMID: 3024029610.2214/AJR.18.19880)
Tong P, Sun D, Chen G, Ni J, Li Y (2015) Biparametric magnetic resonance imaging-based radiomics features for prediction of lymphovascular invasion in rectal cancer. BMC Cancer 23:61. (PMID: 10.1186/s12885-023-10534-w)
Kanda T, Matsuda M, Oba H, Toyoda K, Furui S (2015) Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 277:924–5. (PMID: 2659993210.1148/radiol.2015150697)
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, et al (2015) Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 275:772–82. (PMID: 2574219410.1148/radiol.15150025)
Ye L, Chen Y, Xu H, Xie H, Yao J, Liu J, et al (2022) Biparametric magnetic resonance imaging assessment for detection of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Radiol 32:6480–92. (PMID: 3536275010.1007/s00330-022-08696-5)
Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–97. (PMID: 2346612610.1016/j.ejca.2013.02.001)
Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al (2013) Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 82:2161–8. (PMID: 2403483510.1016/j.ejrad.2013.08.008)
Schrier BP, Peters M, Barentsz JO, Witjes JA (2006). Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 49:698–703. (PMID: 1646453110.1016/j.eururo.2006.01.022)
Hafeez S, Horwich A, Omar O, Mohammed K, Thompson A, Kumar P, et al (2015) Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. Br J Cancer 112:1626–35. (PMID: 25897675443071210.1038/bjc.2015.109)
Liu Y, Bui MM, Xu B (2017) Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis. Cancer Control 24:78–82. (PMID: 2817871810.1177/107327481702400113)
Shah RB, Montgomery JS, Montie JE, Kunju LP (2013). Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 31:1650–5. (PMID: 2260854310.1016/j.urolonc.2012.04.009)
Antunes AA, Nesrallah LJ, Dall’Oglio MF, Maluf CE, Camara C, Leite KR, et al (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33:339–45; discussion 46. (PMID: 1762665010.1590/S1677-55382007000300006)
Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A, Itoh N, et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744–8. (PMID: 1549171310.1016/j.urology.2004.05.003)
Mühlbauer J, Stein R, Younsi N (2021) Bladder cancer in patients with spina bifida: a serious risk. World J Urol 39:1531–7. (PMID: 3263255410.1007/s00345-020-03338-1)
Gelfand M, Weinberg RW, Castle WM (1967) Relation between carcinoma of the bladder and infestation with Schistosoma haematobium. Lancet 1:1249–51. (PMID: 416503810.1016/S0140-6736(67)92714-6)
Gellert LL, Warrick J, Al-Ahmadie HA (2015) Urothelial carcinoma with squamous differentiation--the pathologists׳ perspective. Urol Oncol 33:437–43. (PMID: 2632105710.1016/j.urolonc.2015.07.018)
Dotson A, May A, Davaro F, Raza SJ, Siddiqui S, Hamilton Z (2019). Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. Int J Clin Oncol 24:706–11. (PMID: 3070734210.1007/s10147-019-01409-x)
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, et al (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693–9. (PMID: 2110599110.1111/j.1464-410X.2010.09900.x)
Speir RW, Barboza MP, Calaway A, Masterson TA, Cary C, Koch M, et al (2021) Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter? Clin Genitourin Cancer 19:47–52. (PMID: 3271196110.1016/j.clgc.2020.06.004)
Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, et al (2007) Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 31:1777–87. (PMID: 1804303210.1097/PAS.0b013e31805c9cd9)
Ogbue O, Haddad A, Almassi N, Lapinski J, Daw H (2022) Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes. Transl Androl Urol 11:877–901. (PMID: 35812199926273510.21037/tau-22-43)
Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Shigehara K, et al (2022) Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma. In Vivo 36:2365–70. (PMID: 36099139946392710.21873/invivo.12968)
Mitra AP, Bartsch CC, Bartsch G, Miranda G, Skinner EC, Daneshmand S (2014). Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 32:117–27. (PMID: 2347787810.1016/j.urolonc.2012.08.017)
Gandhi J, Chen JF, Al-Ahmadie H (2022). Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes. Surg Pathol Clin 15:641–59. (PMID: 36344181975681210.1016/j.path.2022.07.003)
Mai KT, Park PC, Yazdi HM, Saltel E, Erdogan S, Stinson WA, et al (2006) Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases. Eur Urol 50:1111–4. (PMID: 1662685910.1016/j.eururo.2005.12.047)
Fritsche HM, Burger M, Denzinger S, Legal W, Goebell PJ, Hartmann A (2008) Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 180:1923–7. (PMID: 1880152510.1016/j.juro.2008.07.035)
Kaimakliotis HZ, Monn MF, Cheng L, Masterson TA, Cary KC, Pedrosa JA, et al (2014) Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 83:1112–6. (PMID: 2458211710.1016/j.urology.2013.12.035)
Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, et al (2016) Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet 48:356–8. (PMID: 26901067482743910.1038/ng.3503)
Sood S, Paner GP (2019). Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections. Arch Pathol Lab Med 143:1562–7. (PMID: 3086549110.5858/arpa.2018-0139-RS)
Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, et al (2013) Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol 189:1656–61. (PMID: 2315958110.1016/j.juro.2012.11.084)
Ricardo-Gonzalez RR, Nguyen M, Gokden N, Sangoi AR, Presti JC, McKenney JK (2012) Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol 187:852–5. (PMID: 2224532410.1016/j.juro.2011.10.145)
Chung AD, Schieda N, Flood TA, Cagiannos I, Mai KT, Malone S, et al (2017) Plasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation. Can Urol Assoc J 11:E50–E7. (PMID: 28163816526251410.5489/cuaj.3789)
Woo S, Ghafoor S, Das JP, Gangai N, Goh AC, Vargas HA (2022). Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival. Urol Oncol 40:108.e1–108.e10. (PMID: 3475005410.1016/j.urolonc.2021.09.017)
Johansson SL, Borghede G, Holmäng S (1999) Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 161:1798–802. (PMID: 1033243810.1016/S0022-5347(05)68807-6)
Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A, Hernández-Hernandez DM (2005) Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol 9:1–5. (PMID: 1569294310.1053/j.anndiagpath.2004.10.001)
Alkibay T, Sözen S, Gürocak S, Işik Gönül I, Poyraz A, Ure I (2009) Micropapillary pattern in urothelial carcinoma: a clinicopathological analysis. Urol Int 83:300–5. (PMID: 1982903010.1159/000241672)
Li Z, Liao H, Tan Z, Mao D, Wu Y, Xiao YM, et al (2017) Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis. Clin Transl Oncol 19:1217–24. (PMID: 2843257210.1007/s12094-017-1658-6)
Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18:1224–32. (PMID: 797794510.1097/00000478-199412000-00005)
McQuitty E, Ro JY, Truong LD, Shen SS, Zhai Q, Ayala AG (2012) Lymphovascular invasion in micropapillary urothelial carcinoma: a study of 22 cases. Arch Pathol Lab Med 136:635–9. (PMID: 2264627010.5858/arpa.2011-0463-OA)
Gaya JM, Palou J, Algaba F, Arce J, Rodríguez-Faba O, Villavicencio H (2010) The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 17:5370–6. (PMID: 20974029)
Mehrnoush V, Ismail A, Zakaria A, Elmansy H, Shahrour W, Prowse O, et al (2021) Micropapillary bladder cancer: an added indication to prophylactic urethrectomy. J Surg Case Rep 2021:rjab501. (PMID: 34804485859811810.1093/jscr/rjab501)
Fan TW, Malhi H, Varghese B, Cen S, Hwang D, Aron M, et al (2019) Computed tomography-based texture analysis of bladder cancer: differentiating urothelial carcinoma from micropapillary carcinoma. Abdom Radiol (NY) 44:201–8. (PMID: 3002222010.1007/s00261-018-1694-x)
Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, et al (2007) Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178:2302–6; discussion 7. (PMID: 1793680310.1016/j.juro.2007.08.038)
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, et al (1998) Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 159:1497–503. (PMID: 955434110.1097/00005392-199805000-00023)
Wang J, Wang FW, Lagrange CA, Hemstreet Iii GP, Kessinger A (2010) Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010. (PMID: 10.1155/2010/454792)
Torenbeek R, Blomjous CE, de Bruin PC, Newling DW, Meijer CJ (1994) Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol 18:241–9. (PMID: 750957410.1097/00000478-199403000-00003)
Sigal SH, Tomaszewski JE, Brooks JJ, Wein A, LiVolsi VA (1991) Carcinosarcoma of bladder following long-term cyclophosphamide therapy. Arch Pathol Lab Med 115:1049–51. (PMID: 1898235)
Stamatiou K, Galariotis N, Michailidis I, Petrakopoulou N, Moustou H, Zizi-Sermpetzoglou A (2010) Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol 51:724–8. (PMID: 21031095296378810.4111/kju.2010.51.10.724)
Perret L, Chaubert P, Hessler D, Guillou L (1998) Primary heterologous carcinosarcoma (metaplastic carcinoma) of the urinary bladder: a clinicopathologic, immunohistochemical, and ultrastructural analysis of eight cases and a review of the literature. Cancer 82:1535–49. (PMID: 955453210.1002/(SICI)1097-0142(19980415)82:8<1535::AID-CNCR16>3.0.CO;2-5)
Murata M, Hasegawa G, Inui K, Ikeda Y, Hasegawa M, Hara N, et al (2020) Urothelial carcinoma with sarcomatoid/osteosarcoma variant of the bladder: A case report. SAGE Open Med Case Rep 8:2050313X20927615. (PMID: 325371647268166)
Young RH (1987) Carcinosarcoma of the urinary bladder. Cancer 59:1333–9. (PMID: 354543510.1002/1097-0142(19870401)59:7<1333::AID-CNCR2820590717>3.0.CO;2-N)
Lopez-Beltran A, Cheng L (2006) Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 37:1371–88. (PMID: 1694991910.1016/j.humpath.2006.05.009)
Holmäng S, Johansson SL (2001) The nested variant of transitional cell carcinoma--a rare neoplasm with poor prognosis. Scand J Urol Nephrol 35:102–5. (PMID: 1141165010.1080/003655901750170425)
Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, et al (2013) Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol 189:1670–5. (PMID: 2314268610.1016/j.juro.2012.11.006)
Murphy WM, Deana DG (1992) The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn’s nests. Mod Pathol 5:240–3. (PMID: 1495929)
Dhall D, Al-Ahmadie H, Olgac S (2007) Nested variant of urothelial carcinoma. Arch Pathol Lab Med 131:1725–7. (PMID: 1797949410.5858/2007-131-1725-NVOUC)
Yamada K, Sasakura Y, Yamada S, Nagano H, Terayama K, Fujita M, et al (2020) MRI features of the nested variant of urothelial carcinoma of the urinary bladder: report of four cases. Abdom Radiol (NY) 45:2279–85. (PMID: 3211213810.1007/s00261-020-02442-5)
Wang W, Li W, Wang K, Wu J, Qiu J, Zhang Y, et al (2023) Integrating radiomics with the vesical imaging-reporting and data system to predict muscle invasion of bladder cancer. Urol Oncol 41:294.e1–294.e8. (PMID: 3652652510.1016/j.urolonc.2022.10.024)
Zheng Z, Xu F, Gu Z, Yan Y, Xu T, Liu S, et al (2021) Integrating multiparametric MRI radiomics features and the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer grading. Abdom Radiol (NY) 46:4311–23. (PMID: 3397882510.1007/s00261-021-03108-6)
Boca B, Caraiani C, Telecan T, Pintican R, Lebovici A, Andras I, et al (2023) MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment. Diagnostics (Basel) 13. (PMID: 3744369210.3390/diagnostics13132300)
Moribata Y, Kurata Y, Nishio M, Kido A, Otani S, Himoto Y, et al (2023) Automatic segmentation of bladder cancer on MRI using a convolutional neural network and reproducibility of radiomics features: a two-center study. Sci Rep 13:628. (PMID: 36635425983718310.1038/s41598-023-27883-y)
معلومات مُعتمدة: P30 CA008748 (MSK) NIH/NCI Cancer Center
فهرسة مساهمة: Keywords: Contrast Media; Diffusion; Magnetic Resonance Imaging; Neoplasm Staging; Transurethral Resection of Bladder; Urinary Bladder Neoplasms
المشرفين على المادة: 0 (Contrast Media)
تواريخ الأحداث: Date Created: 20240607 Date Completed: 20240805 Latest Revision: 20240805
رمز التحديث: 20240805
DOI: 10.1007/s00261-024-04397-3
PMID: 38847848
قاعدة البيانات: MEDLINE
الوصف
تدمد:2366-0058
DOI:10.1007/s00261-024-04397-3